Printer Friendly

CYTOGEN SCIENTISTS HONORED BY R&D COUNCIL OF NEW JERSEY

 PRINCETON, N.J., June 3 /PRNewswire/ -- CYTOGEN Corporation (NASDAQ: CYTO) announced today that two of its founding scientists, President Thomas J. McKearn, M.D., Ph.D., and Vice President of Research and Development John D. Rodwell, Ph.D., will be honored this evening at the 16th annual Thomas Alva Edison Patent Awards of the Research and Development Council of New Jersey.
 McKearn and Rodwell's patent won the Medical/Health category, which is one of three patent awards given annually for the purpose of encouraging creativity and technological, commercial and sociological leadership on the part of New Jersey organizations.
 The patent award was for the U.S. Patent No. 4,671,958, "Antibody Conjugates for the Delivery of Compounds to Target Sites," which, using innovative chemistry, allows diagnostic and therapeutic agents to be effectively attached to antibodies without compromising the ability of the antibodies to target disease. This patent protects the key technology underlying a majority of CYTOGEN Corporation's cancer care products. Two resulting products, OncoScint(R) Colorectal and Ovarian cancer imaging agents, were approved for marketing by the Food and Drug Administration in December 1992. These products are the first monoclonal antibody-based cancer imaging agents approved in the United States. The same technology is being utilized to develop diagnostic agents for breast, lung, prostate and bladder cancers, as well as therapeutic products for ovarian, prostate and bladder cancers.
 McKearn, president of CYTOGEN Corporation, commented, "Twelve years ago, CYTOGEN was started on the concept of doing something with monoclonal antibodies, and the technology protected in this patent was the beginning of that effort." He continued, "It is an honor to be recognized by the scientific community of New Jersey for this invention, which has had an important impact on CYTOGEN's progress as a cancer care company."
 CYTOGEN is a biopharmaceutical company engaged in the development of products for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. CYTOGEN uses its patented and proprietary "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 /delval/
 -0- 6/3/93
 /CONTACT: Mary Beals, director of corporate communications of CYTOGEN, 609-987-8221/
 (CYTO)


CO: CYTOGEN Corporation; Research and Development Council of New Jersey ST: New Jersey IN: MTC SU:

MJ-LJ -- PH030 -- 5179 06/03/93 16:33 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 3, 1993
Words:380
Previous Article:DUFF & PHELPS: CITY OF FARMINGTON, N.M. $154.540 MILLION 5-7/8 PERCENT POLLUTION CONTROL REFUNDING REVENUE BONDS, 1993 SERIES A RATED 'A+'
Next Article:COVENANT BANK RECEIVES FIVE STAR RATING
Topics:


Related Articles
CYTOGEN ANNOUNCES APPOINTMENT OF REGIONAL SALES MANAGERS
CYTOGEN WELCOMES MICHAEL PAULIK AS VICE PRESIDENT OF OPERATIONS
CYTOGEN WELCOMES MARY BEALS AS DIRECTOR OF CORPORATE COMMUNICATIONS
CYTOGEN ELECTS BRUCE R. ROSS TO BOARD OF DIRECTORS
PAMELA M. MURPHY JOINS CYTOGEN AS VICE PRESIDENT CORPORATE COMMUNICATIONS
CYTOGEN ANNOUNCES ELECTION OF WILLIAM C. MILLS III AS CHAIRMAN OF THE BOARD
DR. ROBERT MAGUIRE PROMOTED TO CYTOGEN VP OF MEDICAL AFFAIRS
CYTOGEN BOARD OF DIRECTORS NAMES THOMAS J. MCKEARN AS CHAIRMAN
CYTOGEN Names Graham S. May, M.D., Vice President Medical Affairs And Signs Investor Relations Consultant
CYTOGEN Announces Management Additions

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters